Comparative assessment of tissue cross-reactivity and pharmacokinetic half-life of malaria monoclonal antibodies
By
William R. Fugina
Dallas R. Brown
Shelby Foor
Emma C. Ryan
Samuel Cuevas
Shreeram Nallar
Dawn Wolf
Renita Brown
Jesse P. Deluca
Geoffrey C. Chin
Elizabeth J. Raymond
James T. Raymond
Phil S. Medlin
Sheetij Dutta
June 23, 2026
Clinical Scorecard: Evaluation of Tissue Cross-Reactivity and Pharmacokinetic Longevity of Monoclonal Antibodies Against Malaria
At a Glance
Category Detail
Condition Malaria Key Mechanisms Monoclonal antibodies targeting Plasmodium falciparum circumsporozoite protein (CSP) with improved pharmacokinetics through Fc modifications. Target Population Travelers, military personnel, and pregnant women. Care Setting Clinical development of monoclonal antibodies for malaria prevention.
Key Highlights
Monoclonal antibodies 317 and 311 showed varying degrees of cross-reactivity in human tissues. Modified mAb 311-LS demonstrated improved pharmacokinetics and safety compared to wild-type mAb 311. TCR assay indicated no membrane binding for CSP mAbs, highlighting their specificity. Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Off-target binding and pharmacokinetics are critical considerations in monoclonal antibody development. Patient & Prescribing Data
Individuals at risk of malaria, including travelers and military personnel.
Monoclonal antibodies may provide durable protection against malaria.
Clinical Best Practices
Evaluate tissue cross-reactivity early in monoclonal antibody development. Optimize pharmacokinetics through Fc modifications to enhance therapeutic efficacy. Related Resources & Content
